安杰利尼以1.2亿美元收购Quiver Bioscience,瞄准AI生物技术领域。
Angelini nocks an AI arrow with $120M Quiver Bioscience deal
生物技术与制药领域的最新动态
Angelini nocks an AI arrow with $120M Quiver Bioscience deal
UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies
FDA issues safety alert on Trividia blood glucose monitors
Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials
Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail
MoonLake's phase 2 arthritis win kicks off pivotal year for IL-17 nanobody
Assessing Myelin Formation and Therapeutic Response Using 3D Organoids
iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson’s and First Enrollment in China’s Randomized MSA Trial for NouvNeu004
Supreme Court steps in: Trump's emergency tariffs struck down
Ionis scraps early candidate for Alzheimer’s in people with Down syndrome
Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint
Mainz Biomed looks to shed ColoAlert, shifts focus in US
Chutes & Ladders—Roche taps Aussie oncologist to lead early research
Biohaven charts comeback path after FDA blow, placing bets on obesity
Candel glows brighter with $100M RTW royalty deal to fund prostate cancer drug's launch
Daiichi picks former Novartis CMO John Tsai to head up R&D
White House frustration may have fueled FDA’s Moderna walkback: Politico
Novartis winds down ph. 1 solid tumor program after lacking efficacy
Sanofi backs Altesa's $75M series B to bankroll antiviral's midstage rhinovirus study
Study finds blood test can predict age of Alzheimer's onset